{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:20:01Z","timestamp":1787170801009,"version":"build-2736575974"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-005517"],"award-info":[{"award-number":["INV-005517"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI153355"],"award-info":[{"award-number":["R01 AI153355"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Epidemiol."],"abstract":"<jats:p>Treatment of symptomatic malaria became a routine component of the clinical and public health response to malaria after the second world war. However, all antimalarial drugs deployed against malaria eventually generated enough drug resistance that they had to be removed from use. Chloroquine, sulfadoxine-pyrimethamine, and mefloquine are well known examples of antimalarial drugs to which resistance did and still does ready evolve. Artemisinin-based combination therapies (ACTs) are currently facing the same challenge as artemisinin resistance is widespread in Southeast Asia and emerging in Africa. Here, I review some aspects of drug-resistance management in malaria that influence the strength of selective pressure on drug-resistant malaria parasites, as well as an approach we can take in the future to avoid repeating the common mistake of deploying a new drug and waiting for drug resistance and treatment failure to arrive. A desirable goal of drug-resistance management is to reduce selection pressure without reducing the overall percentage of patients that are treated. This can be achieved by distributing multiple first-line therapies (MFT) simultaneously in the population for the treatment of uncomplicated falciparum malaria, thereby keeping treatment levels high but the overall selection pressure exerted by each individual therapy low. I review the primary reasons that make MFT a preferred resistance management option in many malaria-endemic settings, and I describe two exceptions where caution and additional analyses may be warranted before deploying MFT. MFT has shown to be feasible in practice in many endemic settings. The continual improvement and increased coverage of genomic surveillance in malaria may allow countries to implement custom MFT strategies based on their current drug-resistance profiles.<\/jats:p>","DOI":"10.3389\/fepid.2022.1041896","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T01:27:02Z","timestamp":1670981222000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Breaking the cycle of malaria treatment failure"],"prefix":"10.3389","volume":"2","author":[{"given":"Maciej F.","family":"Boni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14787210.2021.1962291","article-title":"Current and emerging strategies to combat antimalarial resistance","volume":"20","author":"Rasmussen","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B2","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.pt.2012.08.002","article-title":"PfCRT and its role in antimalarial drug resistance","volume":"28","author":"Ecker","year":"2012","journal-title":"Trends Parasitol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1172\/JCI38307","article-title":"The impact of malaria parasitism: from corpuscles to communities","volume":"119","author":"Wellems","year":"2009","journal-title":"J Clin Invest"},{"key":"B4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S1471-4922(02)02249-3","article-title":"Combating malaria in Africa","volume":"18","author":"Trape","year":"2002","journal-title":"Trends Parasitol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0140-6736(03)15330-5","article-title":"WHO, the global fund, and medical malpractice in malaria treatment","volume":"363","author":"Attaran","year":"2004","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1046\/j.1365-3156.1998.00270.x","article-title":"Chloroquine in Africa: critical assessment and recommendations for monitoring and evaluating chloroquine therapy efficacy in sub-saharan Africa","volume":"3","author":"Bloland","year":"1998","journal-title":"Trop Med Int Health"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1093\/infdis\/jir664","article-title":"Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in plasmodium falciparum populations","volume":"204","author":"Mita","year":"2011","journal-title":"J Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/0035-9203(92)90138-3","article-title":"An open randomized comparison of intravenous and intramuscular artesunate in severe falciparum malaria","volume":"86","author":"Hien","year":"1992","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"B9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1056\/NEJM199607113350202","article-title":"A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria","volume":"335","author":"Hien","year":"1996","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/0035-9203(94)90231-3","article-title":"Single dose artemisinin-mefloquine treatment for acute uncomplicated falciparum malaria","volume":"88","author":"Hien","year":"1994","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"B11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/0035-9203(90)90012-4","article-title":"A randomized comparative study of artemisinine and oral quinine in acute falciparum malaria suppositories","volume":"84","author":"Arnold","year":"1990","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/S0140-6736(84)92057-9","article-title":"Randomised comparative study of mefloquine, qinghaosu, and purimethamine-sulfadoxine in patients with falciparum malaria","volume":"324","author":"Li","year":"1984","journal-title":"Lancet"},{"key":"B13","author":"Bosman","year":""},{"key":"B14","author":"Nosten","year":""},{"key":"B15","volume-title":"Guidelines for the treatment of malaria","year":"2006"},{"key":"B16","year":""},{"key":"B17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nature15535","article-title":"The effect of malaria control on plasmodium falciparum in Africa between 2000 and 2015","volume":"526","author":"Bhatt","year":"2015","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1056\/NEJMc0805011","article-title":"Evidence of artemisinin-resistant malaria in western Cambodia","volume":"359","author":"Noedl","year":"2008","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin resistance in plasmodium falciparum malaria","volume":"361","author":"Dondorp","year":"2009","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","article-title":"Evidence of artemisinin-resistant malaria in Africa","volume":"385","author":"Balikagala","year":"2021","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","article-title":"Emergence and clonal expansion of in vitro artemisinin-resistant plasmodium falciparum kelch13 R561H mutant parasites in Rwanda","volume":"26","author":"Uwimana","year":"2020","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/infdis\/jiu491","article-title":"Independent emergence of artemisinin resistance mutations among plasmodium falciparum in Southeast Asia","volume":"211","author":"Takala-Harrison","year":"2015","journal-title":"J Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.12688\/wellcomeopenres.16168.2","article-title":"An open dataset of plasmodium falciparum genome variation in 7,000 worldwide samples","volume":"6","author":"Ahouidi","year":"2021","journal-title":"Wellcome Open Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1207-3","article-title":"Association of mutations in the plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments\u2014a WWARN individual patient data meta-analysis","volume":"17","author":"Amaratunga","year":"2019","journal-title":"BMC Med"},{"key":"B25","year":""},{"key":"B26","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S1473-3099(13)70252-4","article-title":"Novel phenotypic assays for the detection of artemisinin-resistant plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies","volume":"13","author":"Witkowski","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12936-021-03942-5","article-title":"Time to scale up molecular surveillance for anti-malarial drug resistance in sub-saharan Africa","volume":"20","author":"Nsanzabana","year":"2021","journal-title":"Malar J"},{"key":"B28","volume-title":"WHO guidelines for malaria","year":"2022"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1001984","DOI":"10.1371\/journal.pmed.1001984","article-title":"The community as the patient in malaria-endemic areas: preempting drug resistance with multiple first-line therapies","volume":"13","author":"Boni","year":"2016","journal-title":"PLoS Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/0035-9203(86)90248-8","article-title":"A simple model of the build-up of resistance to mixtures of anti-malarial drugs","volume":"80","author":"Curtis","year":"1986","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"B31","doi-asserted-by":"publisher","first-page":"12106","DOI":"10.1073\/pnas.94.22.12106","article-title":"Evaluating treatment protocols to prevent antibiotic resistance","volume":"94","author":"Bonhoeffer","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"B32","doi-asserted-by":"publisher","first-page":"13285","DOI":"10.1073\/pnas.0402298101","article-title":"Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals","volume":"101","author":"Bergstrom","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B33","doi-asserted-by":"publisher","first-page":"14216","DOI":"10.1073\/pnas.0804628105","article-title":"Benefits of using multiple first-line therapies against malaria","volume":"105","author":"Boni","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B34","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.seps.2013.04.001","article-title":"Impact of treatment heterogeneity on drug resistance and supply chain costs","volume":"47","author":"Spiliotopoulou","year":"2013","journal-title":"Socio-Econ Planning Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e758","DOI":"10.1016\/S2214-109X(15)00162-X","article-title":"Optimum population-level use of artemisinin combination therapies: a modelling study","volume":"3","author":"Nguyen","year":"2015","journal-title":"Lancet Global Health"},{"key":"B36","author":"Li","year":""},{"key":"B37","author":"Nguyen","year":""},{"key":"B38","first-page":"265","article-title":"Bacterial evolution and the cost of antibiotic resistance","volume":"1","author":"Lenski","year":"1998","journal-title":"Intl Microbiol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/jac\/dkh044","article-title":"Rifampicin resistance and its fitness cost in Enterococcus faecium","volume":"53","author":"Enne","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"B40","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.drup.2004.08.003","article-title":"Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies","volume":"7","author":"Laufer","year":"2004","journal-title":"Drug Resist Updates"},{"key":"B41","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.actatropica.2005.04.005","article-title":"Fitness of drug-resistant malaria parasites","volume":"94","author":"Walliker","year":"2005","journal-title":"Acta Trop"},{"key":"B42","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.1038\/s41467-018-07370-z","article-title":"The phylogeography and incidence of multi-drug resistant typhoid fever in sub-saharan Africa","volume":"9","author":"Park","year":"2018","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e567","DOI":"10.1016\/S2666-5247(22)00093-3","article-title":"The international and intercontinental spread and expansion of antimicrobial-resistant Salmonella Typhi: a genomic epidemiology study","volume":"3","author":"da Silva","year":"2022","journal-title":"Lancet Microbe"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e01229","DOI":"10.7554\/eLife.01229","article-title":"Fitness benefits in fluoroquinolone- resistant Salmonella Typhi in the absence of antimicrobial pressure","volume":"2","author":"Baker","year":"2013","journal-title":"eLife"},{"key":"B45","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.0014-3820.2005.tb01008.x","article-title":"Evolution of antibiotic resistance by human and bacterial niche construction","volume":"59","author":"Boni","year":"2005","journal-title":"Evolution"},{"key":"B46","doi-asserted-by":"crossref","DOI":"10.1515\/9780691209418","volume-title":"Evolution in changing environments","author":"Levins","year":"1968"},{"key":"B47","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1124\/pr.57.1.4","article-title":"Mechanisms of resistance of malaria parasites to antifolates","volume":"57","author":"Gregson","year":"2005","journal-title":"Pharmacol Rev"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1086\/375419","article-title":"Reemergence of chloroquine-sensitive plasmodium falciparum malaria after cessation of chloroquine use in Malawi","volume":"187","author":"Kublin","year":"2003","journal-title":"J Infect Dis"},{"key":"B49","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1098\/rspb.2006.0015","article-title":"What is the best control strategy for multiple infectious disease outbreaks?","volume":"274","author":"Handel","year":"2007","journal-title":"Proc Biol Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"7588","DOI":"10.1073\/pnas.0611071104","article-title":"The effect of public health measures on the 1918 influenza pandemic in U. S. cities","volume":"104","author":"Bootsma","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B51","doi-asserted-by":"publisher","first-page":"20120207","DOI":"10.1098\/rstb.2012.0207","article-title":"Virulence attenuation during an influenza A\/H5N1 pandemic","volume":"368","author":"Boni","year":"2013","journal-title":"Phil Trans R Soc Lond B"},{"key":"B52","doi-asserted-by":"publisher","first-page":"7582","DOI":"10.1073\/pnas.0610941104","article-title":"Public health interventions and epidemic intensity during the 1918 influenza pandemic","volume":"104","author":"Hatchett","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"B53","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S0140-6736(83)90523-8","article-title":"Changes in malaria incidence after mass drug administraion in Nicaragua","volume":"2","author":"Garfield","year":"1983","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","first-page":"eabe8372","DOI":"10.1126\/science.abe8372","article-title":"Age groups that sustain resurging COVID-19 epidemics in the United States","volume":"371","author":"Monod","year":"2021","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","first-page":"6189","DOI":"10.1038\/s41467-020-19652-6","article-title":"State-level tracking of COVID-19 in the United States","volume":"11","author":"Unwin","year":"2020","journal-title":"Nat Commun"},{"key":"B56","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S2666-5247(22)00155-0","article-title":"Pre-existing partner-drug resistance facilitates the emergence and spread of artemisinin resistance: a consensus modelling study","volume":"3","author":"Watson","year":"2022","journal-title":"Lancet Microbe"},{"key":"B57","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/1475-2875-11-422","article-title":"Policy options for deploying anti-malarial drugs in endemic countries: a population genetics approach","volume":"11","author":"Antao","year":"2012","journal-title":"Malar J"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.08.434496","article-title":"Antimalarial mass drug administration in large populations and the evolution of drug resistance","author":"Nguyen","year":"2021","journal-title":"bioRxiv"},{"key":"B59","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1473-3099(16)30415-7","article-title":"A surrogate marker of piperaquine-resistant plasmodium falciparum malaria: a phenotype\u2013genotype association study","volume":"17","author":"Witkowski","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e0000111","DOI":"10.1371\/journal.pgph.0000111","article-title":"Long-term effects of increased adoption of artemisinin combination therapies in Burkina Faso","volume":"2","author":"Zupko","year":"2022","journal-title":"PLoS Global Public Health"},{"key":"B61","year":""},{"key":"B62","year":""},{"key":"B63","year":""},{"key":"B64","year":""},{"key":"B65","year":""},{"key":"B66","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3185\/pathexo3235","article-title":"Les raisons d\u2019un changement de medicaments de premiere intention pour le traitement du paludisme simple au Burkina Faso","volume":"102","author":"Gansane","year":"2009","journal-title":"Bull Soc Pathol Exot"},{"key":"B67","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12936-022-04225-3","article-title":"Stakeholder perceptions on the deployment of multiple first-line therapies for uncomplicated malaria: a qualitative study in the health district of kaya, Burkina Faso","volume":"21","author":"Hien","year":"2022","journal-title":"Malar J"},{"key":"B68","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12936-022-04180-z","article-title":"Attitudes, practices, and determinants of community care-seeking behaviours for fever\/malaria episodes in the context of the implementation of multiple first-line therapies for uncomplicated malaria in the health district of kaya, Burkina Faso","volume":"21","author":"Kabor\u00e9","year":"2022","journal-title":"Malar J"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e040220","DOI":"10.1136\/bmjopen-2020-040220","article-title":"Protocol for a quasi-experimental study to assess the feasibility, acceptability and costs of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the kaya health district, Burkina Faso","volume":"11","author":"Siribie","year":"2021","journal-title":"BMJ Open"},{"key":"B70","year":""},{"key":"B71","article-title":"Operational challenges of implementing multiple first-line therapies for malaria in endemic countries","author":"Shretta","year":"2008","journal-title":"Manage Sci Health"},{"key":"B72","author":"Yadav","year":""},{"key":"B73","volume-title":"The Sun Also Rises","author":"Hemingway","year":"1926"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e01818","DOI":"10.1128\/AAC.01818-18","article-title":"Changing molecular markers of antimalarial drug sensitivity across Uganda","volume":"63","author":"Asua","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"B75","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1046\/j.1365-3156.2001.00800.x","article-title":"Modelling parasite drug resistance: lessons for management and control strategies","volume":"6","author":"Hastings","year":"2001","journal-title":"Trop Med Int Health"},{"key":"B76","doi-asserted-by":"publisher","first-page":"e7871","DOI":"10.1371\/journal.pone.0007871","article-title":"Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial","volume":"4","author":"Bassat","year":"2009","journal-title":"PLoS One"},{"key":"B77","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.03647-14","article-title":"In vivo selection of plasmodium falciparum pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso","volume":"59","author":"Baraka","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"B78","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1128\/AAC.04181-14","article-title":"Efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for treatment of uncomplicated malaria in children in Zaire and u\u00edge provinces, Angola","volume":"59","author":"Plucinski","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"B79","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4269\/ajtmh.2005.73.826","article-title":"Amodiaquine, sulfadoxine-pyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso","volume":"73","author":"Zongo","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"B80","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4269\/ajtmh.2006.75.162","article-title":"Roles of specific plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso","volume":"75","author":"Dokomajilar","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"B81","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/j.1365-3156.2007.01995.x","article-title":"Chloroquine-resistance molecular markers (pfcrt T76 and pfmdr-1 Y86) and amodiaquine resistance in Burkina Faso","volume":"13","author":"Tinto","year":"2008","journal-title":"Trop Med Intl Health"},{"key":"B82","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1475-2875-7-58","article-title":"Efficacy of amodiaquine in the treatment of uncomplicated falciparum malaria in young children of rural north-western Burkina Faso","volume":"7","author":"Mandi","year":"2008","journal-title":"Malar J"},{"key":"B83","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.actatropica.2009.12.008","article-title":"Selection of pfmdr1 and pfcrt alleles in amodiaquine treatment failure in north-western Burkina Faso","volume":"114","author":"Danquah","year":"2010","journal-title":"Acta Trop"},{"key":"B84","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4269\/ajtmh.2006.75.155","article-title":"Association between mutations in plasmodium falciparum chloroquine resistance transporter and P. Falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in P. Falciparum malaria-infected children in Nigeria","volume":"75","author":"Happi","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e209","DOI":"10.1016\/s2666-5247(20)30094-x","article-title":"Molecular surveillance of antimalarial partner drug resistance in sub-saharan Africa: a spatial-temporal evidence mapping study","volume":"1","author":"Ehrlich","year":"2020","journal-title":"Lancet Microbe"}],"container-title":["Frontiers in Epidemiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fepid.2022.1041896\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T01:27:11Z","timestamp":1670981231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fepid.2022.1041896\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":85,"alternative-id":["10.3389\/fepid.2022.1041896"],"URL":"https:\/\/doi.org\/10.3389\/fepid.2022.1041896","relation":{},"ISSN":["2674-1199"],"issn-type":[{"value":"2674-1199","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"article-number":"1041896"}}